Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Gastric Cancer Drugs Market Valued at Present and by 2029?

The market size for drugs dealing with gastric cancer has surged in recent times. The value of the market is expected to advance from $4.41 billion in 2024 to $4.9 billion in 2025, showing a compound annual growth rate (CAGR) of 11.2%. The past growth was due to factors such as rise in R&D spending in the pharmaceutical industry, increased health care costs, robust economic growth in developing regions, and a fast-growing elderly population.

The market for drugs treating gastric cancer is predicted to experience substantial growth in the coming years. It is projected to expand to “$7.35 billion by 2029 with a compound annual growth rate (CAGR) of 10.7%. This growth throughout the forecast period can be associated with an increasing incidence of gastric cancer, a robust drug pipeline, an uptick in mergers and collaborations, increased healthcare spending, an aging population, and amended FDA regulations that encourages the progression of biologics drugs. Main trends emerging in the forecast period include strategic partnerships and contracts aimed at expanding product range, collaborations with other organizations or government agencies, increasing pipeline studies for the development of gastric cancer drugs, investing in AI technologies to lower R&D expenses, creation of next-gen biologics, and the application of CRISPR-cas9 technology in the development of novel drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

#What Drivers Are Influencing Growth In The Gastric Cancer Drugs Market?

The rise in obesity and the growing number of smokers have led to an increase in people being afflicted with gastric cancer. Unhealthy dietary habits and tobacco consumption escalate the danger of developing stomach cancer. As cited by the UK’s Government Digital Service, it was estimated in May 2023 that the obesity rate amongst individuals aged 18 and above in England had grown from 25.2% in 2022 to 25.9%. As the number of gastric cancer cases rises, so does the demand for gastric cancer medications, thus promoting market growth.

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

What Are The Leading Trends And Opportunities In The Gastric Cancer Drugs Sector?

In the gastric cancer drugs market, numerous firms are developing innovative products, such as anti-PD-1 therapies, to improve treatment results and patient prognosis. Anti-PD-1 therapy is an immunotherapy that targets the PD-1 receptor found on immune cells. For example, in November 2023, US-based pharmaceutical company Merck & Co., Inc. was granted approval by the Food and Drug Administration (FDA) for KEYTRUDA (pembrolizumab), an anti-PD-1 therapy for gastric cancer treatment. KEYTRUDA (pembrolizumab), specifically for combination use with trastuzumab and fluoropyrimidine- and platinum-based chemotherapy, is a first-line treatment for patients with locally advanced inoperable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. The rapid approval was given based on the rate of tumor response and the length of that response.

Which Companies Play A Key Role In The Development Of The Gastric Cancer Drugs Market?

Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

What Are The Key Regional Developments Shaping The Gastric Cancer Drugs Market?

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model